Hunting a cure, Spark reports steady progress on hemophilia B gene therapy as Pfizer preps for pivotal handoff
After some fine tuning on the manufacturing side, Spark Therapeutics $ONCE says it’s racked up a new round of promising results for its Phase I …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
